Harvest One’s Subsidiary Satipharm Talks About Gelpell® Technology

- November 1st, 2019

Harvest One Cannabis Inc. (TSXV:HVT, OTCQX:HRVOF) subsidiary Satipharm AG spoke about the proprietary Gelpell® technology.

Harvest One Cannabis Inc. (TSXV:HVT, OTCQX:HRVOF) subsidiary Satipharm AG spoke about the proprietary Gelpell® technology during the Dublin Marathon Expo in Dublin, Ireland. Satipharm AG is a health and well-being company that specializes in the development and manufacturing of cannabinoid-based products.

Gelpell® technology is designed to help address the bioavailability and consistency issues associated with the delivery of orally-ingested cannabis-based products. Satipharm has completed clinical trials on the Gelpell® capsules with PhytoTech Therapeutics Limited (PTL).  Satipharm representative Matthew Gavin talked about CBD capsules and Gelpell® technology, and said, “it makes it 360 percent more effective than oils, so our phase one and phase two clinical trials showed us data that we can place cannabinoids into micro-gelatin spheres.”

Click here to watch the full video.

Click here to connect with Harvest One (TSXV:HVT) for an Investor Presentation.

Find out what experts are saying about the future of cannabis edibles

 
Read our new report on the 2019 Lift Cannabis Business Conference
 

Get the latest Cannabis Investing stock information

Leave a Reply